Who are Antivipmyn ®'s main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): serum antiscorpion, CroFab, Anti-scorpion venom serum Alacramyn, Anti-scorpion venom serum Birmex.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/antivipmyn.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Antivipmyn ® — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Antivipmyn ® (Antivipmyn ®) competitive landscape: 4 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Antivenom. Area: Toxicology / Emergency Medicine.

marketed Antivenom Toxicology / Emergency Medicine Biologic Live · refreshed every 30 min

Target snapshot

Antivipmyn ® (Antivipmyn ®) — Instituto Bioclon S.A. de C.V.. Antivipmyn is an antivenom that neutralizes venom toxins by binding to and inactivating specific venom components through antibody-antigen interactions.

Comparator set (4 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Antivipmyn ® TARGET	Antivipmyn ®	Instituto Bioclon S.A. de C.V.	marketed	Antivenom
serum antiscorpion	serum antiscorpion	Laboratorios de Biologicos y Reactivos de México, S.A. de C.V.	marketed	Antivenom (polyclonal antiserum)	Scorpion venom toxins (multiple epitopes)
CroFab	CroFab	Instituto Bioclon S.A. de C.V.	marketed	Antivenom (polyclonal antibody fragments)	Crotalid venom toxins (phospholipase A2, serine proteases, metalloproteinases)
Anti-scorpion venom serum Alacramyn	Anti-scorpion venom serum Alacramyn	Laboratorios de Biologicos y Reactivos de México, S.A. de C.V.	phase 3	Antivenom serum
Anti-scorpion venom serum Birmex	Anti-scorpion venom serum Birmex	Laboratorios de Biologicos y Reactivos de México, S.A. de C.V.	phase 3	Antivenom (polyclonal antiserum)	Scorpion venom toxins (multiple components including neurotoxins)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Antivenom class)

Instituto Bioclon S.A. de C.V. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Antivipmyn ® — Competitive Intelligence Brief. https://druglandscape.com/ci/antivipmyn. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab